MIT Researchers Use AI to Design New Antibiotics for Drug-Resistant Bacteria
Massachusetts Institute of Technology (MIT) researchers have developed novel antibiotics using generative AI to combat drug-resistant bacteria, including MRSA and gonorrhea, announced in a press release. The team designed over 36 million potential compounds, screening them for antimicrobial properties, resulting in structurally distinct antibiotics that disrupt bacterial cell membranes.
The research involved two AI approaches: one focused on designing molecules based on a specific chemical fragment, and the other allowed the AI to generate molecules freely. This led to the discovery of two promising compounds, NG1 and DN1, which showed effectiveness against drug-resistant Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus (MRSA) in laboratory and animal tests.
The study, published in the journal Cell, highlights the potential of AI in expanding the chemical space for antibiotic discovery, offering a new strategy to address the growing issue of antibiotic resistance. The research was supported by various organizations, including the U.S. Defense Threat Reduction Agency and the National Institutes of Health.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Unisys Publishes AI Evaluation Framework for Drug Repurposing
MediSights Reports Study Using AI Agents for Myeloma Market Research
AINGENS Warns AI Tool Fragmentation Complicates Medical Affairs Work
Lunai Bioworks Tests AI Chemical Risk Screening Model
Standigm and Protai Start AI Molecular Glue Research Program
Daily AI Brief: the AI news that matters, in your inbox.